Macular oedema (retinal vein occlusion) - dexamethasone (TA229)
Fast, easy summary view of NICE guidance on 'eye conditions '
Dexamethasone intravitreal implant for the treatment of macular oedema caused by retinal vein occlusion (RVO)
NICE recommends dexamethasone intravitreal implant as a possible treatment for some people with macular oedema due to retinal vein occlusion (see below).
You should be able to have dexamethasone intravitreal implant if:
- you have macular oedema due to blockage of the central retinal vein, or
you have macular oedema due to blockage of a branch retinal vein, and
- laser treatment has not helped, or
- laser treatment is not suitable.
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE recommended dexamethasone intravitreal implant because it improves vision compared with best supportive care. Although it costs more, this was justified by the benefits provided.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: eye conditions
- None found
This page was last updated: 22 November 2013
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA229 Mewnblaniad dexamethasone yn y llygad ar gyfer oedema macwlaidd o ganlyniad i rwystr yn y wyth´en retinol: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.